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introduction: Systemic lupus erythematosus (SLE) is characterized by an 
enhanced risk of atherosclerosis and cardiovascular diseases (CVD). Human 
serum paraoxonase 1 (PON1), an antioxidant enzyme closely associated with 
high density lipoprotein (HDL), has been implicated in the prevention of low 
density lipoprotein (LDL) oxidation, and these may provide HDL-associated 
protection against atherosclerosis. 
the aim: Our objective was to evaluate PON1 activity and genotypes in SLE 
patients and their relationships to cardiovascular complications and some other 
risk factors of cardiovascular diseases in those patients. 
Patient and Methods: Thirty SLE patients, subdivided into patients with CVD 
and without CVD, and fifteen matched healthy control subjects were studied. 
Laboratory investigations included lipid profile, lupus anticoagulants (LA), 
anticardiolipin antibodies (aCL). PON1 activity was determined by paraoxon 
substrate. PON1 genotyping was conducted by PCR amplification, followed by 
polymorphism-specific restriction enzyme digestion and gel electrophoresis. 
results: Our study revealed that PON1 activity was significantly decreased 
in SLE patients groups compared to controls and in SLE patients with CVD 
compared to those without CVD (p<0.001). PON1 activity was significantly 
negatively correlated with total cholesterol, LDL-C and LDL-C/HDL-C ratio, 
positively correlated with HDL-C but not significantly correlated with triglyc-
erides, disease activity, LA or aCL antibodies. As regard PON1 192 gene poly-
morphism, there was significant increase in B allele frequency in SLE patients 
with CVD compared to those without CVD and control groups, while no sig-
nificant difference was found between SLE patients without CVD and control 
group. As regard PON1 55 gene polymorphism, there was no significant dif-
ference in genotype distribution or allele frequency between the three groups. 
The Odds ratio of development of CVD in SLE patients who carry PON1 192B 
allele was 6 (95% CI 1.2-30.7, p<0.05). PON1 activity determined by paraoxon 
substrate was significantly higher in BB and LL, intermediates in AB and LM, 
and lower in AA and MM genotypes. 
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conclusion: The decreased PON1 activity and the increased PON1 192B 
allele frequencies in SLE patients may have a role in development of cardio-
vascular complications. Further studies on large number of patients of PON1 
gene polymorphisms of are needed to elucidate this relationship.
introDUction                                 
Systemic lupus erythematosus (SLE) 
is a chronic inflammatory autoimmune 
disease characterized by the production 
of autoantibodies against multiple an-
tigens1. Premature atherosclerosis has 
been recognized as an important cause 
of morbidity and mortality in SLE2, and 
coronary artery disease (CAD) accounts 
for up to 30% of all deaths in some re-
ported series3. Established risk factors 
for CAD in the general population are 
insufficient to explain the increased risk 
in SLE4. Specific factors such as steroid 
treatment, chronic inflammation, and re-
nal disease could account for enhanced 
atheroma formation5. Previous studies 
have reported that SLE is characterized 
by atherogenic lipid profile6,7. Further-
more, several studies have demonstrat-
ed a relationship between low density 
lipoprotein (LDL) oxidation and aPL 
in SLE8,9 and it has been proposed that 
an immune response of aPL to oxidized 
LDL may play a role in the pathogen-
esis of atherosclerosis in SLE.10
Paraoxonase 1 (PON1) is an enzyme 
with antioxidant activity, which circu-
lates in plasma attached to high density 
lipoproteins (HDL)11. Although the nat-
ural substrate(s) of this enzyme are un-
known, it is capable of the hydrolysis of 
a variety of xenobiotics, including or-
ganophosphates and aryl esters that are 
common components of insecticides 
and nerve agents12. Paraoxonase has 
been shown to metabolize lipid-soluble 
radicals and contribute to the HDL me-
diated prevention of LDL oxidation13, 
suggesting that it plays an important 
role in the anti-inflammatory effect of 
HDL. Because oxidized LDL contrib-
utes to the development of atheroscle-
rosis, studies have examined whether 
paraoxonase activity is associated with 
cardiovascular disease risk. Reduced 
enzyme activity was shown in patients 
with cardiovascular disease (CVD).14,15
The PON1 gene maps to human chro-
mosome 7q21.3 at 94.6 Mb, which is 
in close proximity to a linkage peak on 
7q21.1 at 77.5 Mb for SLE16.   Thus, 
PON1 is both a potential positional and 
a potential biologic candidate gene for 
SLE17. PON1 gene contains 2 polymor-
phisms, both of which are due to amino 
acid substitutions; PON1 Q192R, the 
Gln (Q) to Arg (R) substitution at amino 
acid 192, which are also termed the A 
and B isoforms, respectively, and PON1 
L55M, the Leu (L) to Met (M) substitu-
tion at amino acid 5518,19. The rates of 
different substrate hydrolysis are quite 
variable within PON1 genotypes (at 
least 13-fold) and represent phenotypes 
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that can add information about PON1 
status beyond genotyping alone20. It has 
been shown that the PON1 genetic poly-
morphisms may be an independent risk 
factor for coronary artery disease; both 
the 55L and 192B genotype have been 
shown to be associated with increased 
susceptibility to CAD.14,21
Our objective was to evaluate PON1 
activity and genotypes in SLE patients 
and study their relationships to cardio-
vascular complications and some other 
risk factors of cardiovascular diseases 
in those patients.
Patient anD MetHoDS                 
Thirty SLE patients attending outpa-
tients’ clinic and inpatients’ department 
of Rheumatology and Rehabilitation, 
Zagazig University Hospitals and fif-
teen age, sex and body mass index 
(BMI) matched healthy control subjects 
were enrolled in the study. All of the 
SLE patients met the American Col-
lege of Rheumatology revised criteria 
for classification of the disease22,23. Lu-
pus disease activity was assessed using 
SLE disease activity index (SLEDAI) 
score24. All parameters that are known 
to influence PON1 activity, such as 
smoking, chronic renal failure, neph-
rotic syndrome, diabetes, uncontrolled 
hypertension, and lipid lowering drug 
intake, were excluded25. All patients 
were on no more than 8 mg maintenance 
prednisone (or equivalent steroid), as 
larger doses cause dyslipidaemia both 
on short and long term bases. Patients 
were subdivided according to presence 
of cardiovascular diseases (CVD) into 
two groups; 18 SLE patients without 
CVD and 12 SLE patients with CVD 
(4 with history of myocardial infarction 
at least 2 months ago, 6 with angina and 
2 with cerebral stroke).
Blood samples were obtained after 12 
hours fasting. Sera were separated for 
lipid profile, PON1 activity and anti-
cardiolipin antibodies (aCL) determi-
nation. Citrated plasma was used for 
lupus anticoagulants (LA) detection 
and EDTA blood were used for PON1 
genotyping.
laboratory investigations:Total cho-
lesterol, triglycerides were determined 
on ADVIA 1650 autoanalyzer (Siemens 
Medical Solutions Diagnostic, USA). 
HDL-C was determined using Eli-tech 
kit26 (ELI-TECH Diagnostics, France). 
LDL-C was calculated according to 
Friedewald’s equation.27
Lupus anticoagulant was detected 
by dilute russell’s viper venom time 
(DRVVT) based lupus anticoagulant 
detection system (LADS) kit (Tulip 
dianostics).28
Anticardiolipin antibodies were quanti-
tated using indirect solid phase enzyme 
immunoassay (ELISA) for the mea-
surement of IgG and IgM class autoan-
tibodies (orgentec Diagnostika GmbH, 
Germany). aCL IgG  ≥10 GPL U/ml 
and aCL IgM ≥7 MPL U/ml were 
considered positive.
PON1 activity assay was performed 
using paraoxon (O,O-diethyl-O-p-ni-
trophenyl phosphate; Sigma-Aldrich, 
Germany) as a substrate according to 
the method described by Mackness29. 
The assay mixture included 2.0 mM/L 
paraoxon and 2.0 mM/L CaCl2 in 0.1 
M/L Tris-HCl buffer (pH 8.0). To 350 
µL of reagent mixture, 10µL of serum 
was added and incubated for 17 sec-
onds. The hydrolysis rates of paraoxon 
were determined by measuring the re-
leased p-nitrophenol at 405 nm at 37°C 
for 3 minutes on Microlab 300 (Vital 
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Scientific, the Netherlands). Blank was 
included to correct for the spontaneous 
hydrolysis of paraoxon. Enzyme ac-
tivities were expressed in international 
units (U) per litre of sera. An interna-
tional unit is the amount of hydrolyzed 
substrate in µmol per minute. Extinc-
tion coefficient of p-nitrophenol at 405 
nm is17, 000/M/cm.
Pon1 genotyping: Total genomic 
DNA was purified from buffy coat sam-
ples using the E.Z.N.A. ™ Blood DNA 
Kit (Omega – biotek. Inc). Genomic 
DNA samples were stored at -20ºC until 
genotyping analysis. PON1 genotypes 
were determined by PCR according 
to previously published protocols18,19. 
For the polymorphism at position 192, 
sense primer 5´ ATTGTTGCTGTGG 
5´GACCTGAG 3´ and antisense primer 
CACGCTAAACCCAAATACATCT-C 
3´, which encompass the 192 poly-
morphic region of the human PON1 
gene, were used. For the polymor-
phism at position 55, sense primer 5´ 
GAAGAGTGATGTATAGCCCCAG 
3´ and antisense primer ´TTTAATC-
CAGAGCTAATGAAAG-CC 3´ were 
used. 
Amplification of DNA was performed 
by puReTaq Ready- To- Go PCR Beads 
(Amersham Biosciences). The PCR re-
action mixture contained 5 µl of tem-
plate DNA, 3 µl of each primer (100 
uM/L) [Operon] in a tube containing 
one PCR bead [200 uM of each dNTP 
in 10 mM Tris - HCL (pH 9.0), 50 mM 
HCL and 1.5 mM MgCl2 and 2.5 U 
Taq DNA polymerase].The following 
temperature scheme was performed for 
the amplification using thermal cycler 
(Gene Amp, PCR system 9700). After 
denaturing the DNA for 5 min at 95°C, 
the reaction mixture was subjected to 
46 cycles of 1 min of denaturation at 
94°C, 30 s of annealing at 61°C and 1 
min of extension at 72°C for the poly-
morphism at position 192. The 99 bp 
PCR product was digested with 8 units 
of AlwI restriction endonuclease (New 
England Biolabs, Cambridge, MA, 
U.S.A.) overnight at 37°C. The digest-
ed products were separated by electro-
phoresis on a 3% (w/v) agarose gel and 
visualized using ethidium bromide. The 
B genotype (arginine) contains a unique 
AlwI restriction site which results in 
products of 66 and 33 bp, whereas the 
A genotype (Glutamine) will not be cut, 
allowing the PON1 192 genotype to be 
determined (Figure1).
For the polymorphism at position 55, 
the PCR reaction and cycling were the 
same as described above, except that 30 
cycles were carried out. The PCR prod-
uct (170 bp) was digested with NlaIII 
(New England Biolabs) in the presence 
of bovine serum albumin (overnight 
at 37°C).The digested products were 
separated and identified as above. The 
L genotype (leucine) does not contain 
an NlaIII site, whereas the M genotpye 
(methionine) does contain an NlaIII 
site, giving rise to products of 126 and 
44 bp (Figure 2).
Statistical analysis: Data were ex-
pressed as mean ± SD for quantitative 
variables, number and percentage for 
qualitative ones. ANOVA, t test, χ2, 
and Pearson correlation were used for 
analysis of results .Odds ratio (OR) and 
95% confidence interval (CI) were per-
formed to predict the effect of PON1 
genotypes on development of SLE and 
CVD. A P-value < 0.05 was considered 
significant. Analysis was performed 
with the SPSS statistical package ver-
sion 10 (SPSS Inc., Chicago, IL).
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reSUltS                                              
The demographic and laboratory char-
acteristics of control group and SLE 
patients are presented in table 1. No 
significant differences were detected 
in age, sex, BMI and disease activity 
in the studied groups. Total cholesterol, 
LDL-C, LDL-C/HDL-C ratio and trig-
lycerides were significantly increased 
and HDL-C was significantly decreased 
in patients groups compared to controls 
(p<0.001). LA and the number of pa-
tients with positive LA and aCL IgG 
were significantly increased in patients 
with CVD compared to those without 
CVD (p<0.001, <0.05 respectively) 
while no significant difference was 
found in aCL IgM in patients groups 
(p>0.05). As regard PON1 activity, it 
was significantly decreased in patients 
groups compared to controls and in 
patients with CVD compared to those 
without CVD (p<0.001). 
On studying the correlation between 
PON1 activity and other studied clini-
cal and laboratory parameters in SLE 
patients, total cholesterol, LDL-C 
and LDL-C/HDL-C ratio were sig-
nificantly negatively correlated while 
HDL-C was significantly positively 
correlated with PON1 activity (p<0.05, 
0.01,<0.05,<0.01 respectively). Dis-
ease activity, LA, and aCL antibodies 
were not significantly correlated with 
PON1 activity (p>0.05) Table 2.
The distribution of PON1 55 and 192 
genotypes and allele frequency in con-
trols and patients groups are reported 
in table 3. PON1 55 genotype, allele 
frequency and the percentage of pa-
tients carrying L allele were not sig-
nificantly different among the studied 
groups (p>0.05). As regard PON1 192 
genotype distribution, there was signifi-
cant increase in AB, BB and decrease 
in AA genotypes in SLE patients with 
CVD compared to those without CVD 
and control groups (p<0.05). Patients 
with CVD had higher frequency of 
PON1 192B allele compared to pa-
tients without CVD and control groups 
(p<0.01). The percentage of carriers of 
PON1 192B allele was significantly in-
creased in patients with CVD compared 
to patients without CVD and controls 
(p<0.05). While, no significant differ-
ence was detected between controls 
and patients without CVD in PON1 
192 genotype distribution or allele fre-
quency.
There was no significant association 
between PON1 gene polymorphism and 
the risk of SLE. The odds ratio of devel-
opment of SLE in PON1 55L allele car-
riers was 1.4 (95% CI 0.2-9.3, P>0.05).
Although there was increased risk of 
development of SLE in PON1 192B al-
lele carriers, this increase did not reach 
the statistical significance (OR 4, 95% 
CI 0.9-17.1, P>0.05). There was sig-
nificant increase in the risk of develop-
ment of CVD among SLE patients who 
carry PON1 192B allele (OR 6, 95%CI 
1.2-30.7, P<0.05).While no significant 
increase in the risk of CVD in SLE pa-
tients who carry PON1 55L allele (OR 
0.3, 95% CI 0.02-3.7, P>0.05).
The relationship between PON1 activ-
ity and different PON1 genotypes is 
presented in table 4. As regard PON1 
55 genotypes, PON1 activity using 
paraoxon as substrate was significantly 
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higher in LL, intermediate in LM, and 
lower in MM genotypes in control and 
patients groups (p<0.05). As regard 
PON1 192 genotype, PON1 activity 




1        2     3     4     5       6       7      M
Fig. 1: The electrophoresis of the PCR products 
of the PON1 genotype 192. Lanes 1,2,5,6 repre-
sent AA genotype, lanes 3, 7 represent AB geno-
type, lane 4 represents BB genotype, lane 8(M) 




1        2     3     4      5      6       7      M
Fig. 2: The electrophoresis of the PCR products 
of the PON1 genotype 55. Lanes 2, 6 represent 
LL genotype; lanes 1, 4 represent MM genotype, 
lanes 3, 5, 7 represent LM genotype, and lane 
8(M) represents 20 bp DNA marker.
AA genotype in control group (p<0.05), 
and higher in BB, intermediate in AB, 
and lower in AA genotype in patients 
group (p<0.01). 









of significance P 
Age   (years) 43.2±4.8 40.5±8.7 39.9±5 F=1.1 > 0.05
¶Males 5(33) 5(28) 3(25) χ2=0.2 > 0.05
BMI (kg/m2) 22.5±2.9 23.4±3.8 24.7±2.5 F=1.59 > 0.05
 SLEDAI NA 6.2±2.1 7.1±1.8 t=-1.2 > 0.05
Total Cholesterol (mg/dl) 171.6±16.3 192.9±22a 209.2±28.7a F=9.6 < 0.001
HDL-C (mg/dl) 52.6±4.3 45.7±9.7b 38.7±5.2b F=12.6 < 0.001
LDL-C (mg/dl) 93.9±15.6 107.6±25.7b 133.5±26.5b F=9.9 < 0.001
LDL-C/HDL-C ratio 1.79±0.34 2.56±1.1 b 3.5±0.8 b F=13.4 < 0.001
Triglycerides (mg/dl) 125.5±11.5 194.5±24a 196.8±28.8a F=49.5 < 0.001
LA        (sec) 34.2±5.7 43.3±7.5b 50.2±11.7b F=6.3 < 0.001
aCL IgG (GPL U/ml) 5.29±1.6 10.4±8.2a 14.3±13.1a F=3.8 < 0.05
         ¶No of positive cases NA 5(28) 5(42) χ2=7.2 < 0.05
aCL IgM (MPL U/ml) 3.9±1.4 6.3±6.8a 8.4±6.3a F=2.3 > 0.05
         ¶No of positive cases NA 3(17) 4(33) χ2=5.6 > 0.05
PON1 activity (U/l) 217.3±55.2 118.6±64.5b 71.8±36.1b F=9.5 < 0.001
Values are represented  means± SD, (n) the number of observations. 
¶Results are expressed as frequency (%). 
NA: not applicable.                                       
a : Significant difference with control group b : Significant difference with all groups. 
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table 2: Correlation between paraoxonase 1 activity, and other clinical and laboratory param-
eters in SLE patients.
    Pr              Variables               
>0.05-0.23               SLEDAI 
<0.05*-0.46     Total Cholesterol (mg/dl)
<0.01**0.52          HDL-C (mg/dl)
<0.01**-0.53          LDL-C (mg/dl)
<0.05*-0.43     LDL-C/HDL-C ratio
> 0.050.11    Triglycerides (mg/dl)
>0.05-0.25            LA (sec)
>0.05-0.25    ACL IgG (GPL U/l)
>0.05-0.19   ACL IgM (MPL U/l)
 * Significant                                                                          ** Highly significant
table 3: Distribution of PON 55 and 192 genotypes and allele frequencies in the studied 
groups.








           PON 55 Genotypes No (%) 
1.35 > 0.05
LL 8 (53.3) 10(55.5) 7(58.3)
LM 5 (33.3) 7(38.9) 3(25)
MM 2(13.4) 1(5.6) 2(16.7)
               Allele frequencies (%)
         L allele 70 75 71
0.24 > 0.05
        M allele 30 25 29
L alleles Carriers No (%) 13(86.7) 17(94.4) 10(83.3)
1.01 > 0.05
Non L alleles carriers No (%) 2(13.3) 1(5.6) 2(16.7)
          PON 192 Genotypes No (%)
9.63 < 0.05
AA 12 (80) 12(66.7) 3(25)*
AB 3 (20) 5(27.8) 7(58.3)*
BB 0(0) 1(5.6) 2(16.7)*
               Allele frequencies (%)
         A allele  90 81 54*
10.14 < 0.01
        B allele  10 19 46*
            B alleles Carriers No (%) 3(20) 6(33.3) 9(75)*
8.95 < 0.05
           Non B alleles carriers No (%) 12(80) 12(66.7) 3(25)*
* Significant difference with other groups.
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DiScUSSion                                         
Previous studies have shown that low 
serum PON1 activity is associated with 
CAD14,15,30,31, and that PON1- knock-
out mice are susceptible to atheroscle-
rosis32. Since SLE patients have up to 
a 50% increased risk of developing 
CAD7, it is reasonable to postulate that 
PON1 activity may also be associated 
with SLE risk.
Our study revealed significantly lower 
PON1 activity in SLE patients com-
pared to controls. Similar results were 
reported by other studies6,17,33,34. Re-
duced PON1 activity can be an inde-
pendent risk for atherosclerosis in SLE 
as there were no correlations between 
disease activity, LA, aCL antibodies 
and low PON1 in SLE patients. Similar 
results were observed by Delgado Al-
ves et al.6, Kiss et al.33 and Tripi et al.17. 
However, a decrease in PON1 activity 
in patients with different autoimmune 
conditions and with aCL antibodies has 
been described35. The mechanism of 
decreased PON1 activity in SLE and 
whether it is a cause or a consequence 
of the disease is unclear. Since inflam-
mation and proinflammatory cytokines 
are associated with low PON1 activi-
ty36-38, reduced PON1 activity could be 
due to inflammation in SLE patients. 
Negative correlations between PON1 
and C-reactive protein and fibrinogen 
and SLE patients have been described17. 
Inhibition of PON1 by increased oxida-
tive stress which has been implicated in 
the pathogenesis of SLE has been also 
considered.39
The last two decades have seen accu-
mulation of evidence suggesting the 
role of PON1 in atherogenesis and 




n Pon1 levels (U/l) n Pon1 levels (U/l)
        PON1 55 Genotype
LL 8 210.9±54 17 120.1±59.2
LM 5 171.5±25.2 10 68.9±55.1
MM 2 95±7.1† 3 29±10.4†
         Test of significance                   F = 5.8                      F = 4.93
P                  < 0.05                      < 0.05
PON1 192 Genotype
AA 11 165.7±43.6 16 71.7±42.8
AB 4 247.7±64.3 11 106.6±63.2
BB 0 -- 3 199±46.1§
Test of significance                    t= -2.68                       F = 7.9
P                 < 0.05                       < 0.01
Values are  represented as means± SD, (n) the number of observations.
† Significant difference with LL genotype.       
§ Significant difference with other PON1 192 genotypes.
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coronary heart disease14,21. Our current 
findings were that low serum PON1 
activity in SLE patients with CVD 
compared to those without CVD and 
controls. This result confirms the previ-
ous observation of low PON1 activity 
in SLE patients with atherothrombotic 
events compared to those without such 
complication.33
A variety of physiologic roles for PON1 
have been proposed, primarily related 
to its anti-atherosclerotic activity. It is 
believed that PON1 protects against 
the action of oxidized LDL by protect-
ing LDL from oxidation, participating 
in the destruction of oxidized phos-
pholipids, and decreasing macrophage 
uptake of oxidized LDL. Secondary ef-
fects of this activity include reduction 
of monocyte adhesion to endothelial 
cells and macrophage chemotaxis that 
would normally occur due to oxidized 
phospholipids.10,21
In this study, we found no significant 
difference in distribution of PON1 55 
genotypes and allele frequencies be-
tween patients and control groups. No 
significant differences in PON1 192 
genotypes and allele frequencies were 
found between controls and patients 
without CVD. The results of our study 
indicate that the PON1 gene polymor-
phism is not related to genetic suscepti-
bility to SLE. In contrast to our results 
tripi et al.17 reported significant associa-
tion between PON1 55L but not PON1 
192 genotypes and SLE risk. 
Our data revealed significant increase 
in PON1 192B allele in SLE who had 
cardiovascular complication compared 
to those without cardiovascular compli-
cation and control groups. Odds ratio of 
development of CVD in SLE patients 
who carry PON1 192B allele was 6.The 
associations between PON1 192B al-
lele and CVD have been previously 
reported13,14,21. PON1, being exclusively 
associated with HDL and apolipopro-
tein A-1, could synergistically contrib-
ute towards cardiovascular disease risk 
in SLE.34
The PON1 polymorphism has substan-
tial influence on PON1 activity deter-
mined with paraoxon, which has been 
replicated in almost all published stud-
ies. PON1 192 and 55 polymorphisms 
explained 46% and 16% of the varia-
tions in PON1 activity toward paraox-
on40. Our data showed that levels of 
PON1 activity tested with paroxon 
were highest in subjects with BB and 
LL genotypes, intermediates in those 
with AB and LM genotypes and lowest 
in those with AA and MM genotypes. 
Our data is consistent with the previous 
reports.17, 40
Since the natural substrate of PON1 is 
still unknown and the PON1 isoforms 
can have opposite effects with differ-
ent substrates, it is possible that these 
variants behave differently with the 
physiologic substrate17. HDL isolated 
from BB homozygotes, although most 
active in the hydrolysis of paraoxon, is 
much less effective at protecting LDL 
against lipid peroxidation than HDL 
from either AA homozygotes or AB 
heterozygotes13,41. Mackness et al.42 and 
Aviram et al.43 demonstrated that puri-
fied PON1 A (low activity phenotype) 
was more effective than PON1 B in 
protection against LDL peroxidation.
Our results revealed that PON1 activity 
was significantly negatively correlated 
with total cholesterol, LDL-C, LDL-C/
HDL-C ratio and positively correlated 
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with HDL-C in SLE patients. In con-
trast to these results Kiss et al.33 report-
ed no correlation between PON1 activi-
ty and lipid parameters in SLE patients. 
Lipid and lipoprotein levels have been 
associated with PON1 activity or geno-
types in some44,45 but not all40,46 studies. 
PON1 genotype was significantly as-
sociated with variation in the plasma 
concentration of HDL-C, LDL-C, and 
triglycerides47. Homozygotes for the 
low-activity allele of PON1 had a less 
atherogenic lipoprotein profile than did 
heterozygotes and homozygotes for the 
high-activity allele.48
There are nearly 200 single nucleotide 
polymorphisms (SNPs) in PON117, and 
this study focused on  two of that genet-
ic variation. Other SNPs in PON1 may 
play a role, or perhaps less common or 
yet undiscovered DNA sequence varia-
tion in PON1 may affect SLE risk. Gene 
– gene and gene–environment interac-
tions, not investigated in this study, are 
thought to play an important role in the 
development of complex diseases such 
as SLE and CVD, and examination of 
these relationships may reveal addition-
al information.
conclUSion                                                
PON1 activity was significantly de-
creased in SLE patients and more sig-
nificantly decreased in SLE patient 
with cardiovascular complications. The 
decrease in PON1 activity may have 
significant effect on development of 
cardiovascular complications in those 
patients as it is correlated with athero-
genic lipid profile. PON1 192B allele is 
associated with SLE related cardiovas-
cular complications but not with SLE. 
Further studies with large number of 
patients are needed to identify the role 
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